An update on satraplatin: the first orally available platinum anticancer drug

Bibliography

• KELLAND LR, SHARP SY: Platinum compounds in cancer therapy. Curr. Opin. Oncol. Endo. & Metabolic Invest. Drugs (1999) 1:380–385.
   Google Scholar
• GIANDOMENICO CM, ABRAMS MJ, MURRER BA et al.: Synthesis and reactions of a new class of orally active PT(IV) antitumor complexes. In: Platinum and Other Metal Co-ordination Compounds in Cancer Chemotherapy. Howell SB (Ed.) Plenum Press, New York, USA (1991):93.
   Google Scholar
• VAN HENNIK MB, VAN DER VIJGH WJF, KLEIN I,VERMORKEN JB, PINEDO HM: Human pharmacoki-netics of carboplatin after oral administration. Cancer Chemother. Pharmacol. (1989) 23:126–127.
   PubMed Web of Science ®Google Scholar
• KELLAND LR, ABEL G, MCKEAGE MJ et al.: Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res. (1993) 53:2581–2586.
   PubMed Web of Science ®Google Scholar
• ••First description of in vitro and in vivo antitumour propertiesof satraplatin.
   Google Scholar
• MELLISH KJ, KELLAND LR, HARRAP KR: In vitro platinumdrug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Br. J. Cancer (1993) 68:240–250.
   PubMed Web of Science ®Google Scholar
• TWENTYMAN PR, WRIGHT KA, MISTRY P, KELLAND LR,MURRER BA: Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin. Cancer Res. (1992) 52:5674–5680.
   PubMed Web of Science ®Google Scholar
• KELLAND LR, JONES, GWYNNE JJ et al.: Antitumouractivity of orally administered ammine/amine platinum (IV) dicarboxylate complexes against a panel of human ovarian carcinoma xenografts. Int. J. Oncol. (1993) 2:1043–1048.
   PubMed Web of Science ®Google Scholar
• ROSE WC, CROSSWELL AR, SCHURIG JE, CASAZZA AM:Preclinical antitumor activity of orally administered platinum (IV) complexes. Cancer Chemother. Pharmacol. (1993) 32:197–203.
   PubMed Web of Science ®Google Scholar
• MCKEAGE MJ, KELLAND LR, BOXALL FE et al.: Schedule dependency of orally administered bis-acetato-ammine- dichloro-cyclohexylamine-platinum(IV) (FM216) in vivo. Cancer Res. (1994) 54:4118–4122.
   PubMed Web of Science ®Google Scholar
• ••Preclinical studies showing satraplatin benefit with dailydosing for five days versus single bolus of satraplatin
   Google Scholar
• ROSE WC: Combination chemotherapy involving orally administered etoposide and JM-216 in murine tumor models. Cancer Chemother. Pharmacol. (1997) 40:51–56.
   PubMed Web of Science ®Google Scholar
• MCKEAGE MJ, MORGAN SE, BOXALL FE, MURRER BA, HARD GC, HARRAP KR: Preclinical toxicology and tissue platinum distribution of novel oral antitumour platinum complexes: ammine/amine platinum(IV) dicarboxylates. Cancer Chemother. Pharmacol. (1994) 33:497–503.
   PubMed Web of Science ®Google Scholar
• MCKEAGE MJ, MORGAN SE, BOXALL FE, MURRER BA, HARD GC, HARRAP KR: Lack of nephrotoxicity of oral ammine/amine platinum(IV) dicarboxylate complexes in rodents. Br.J.Cancer(1993) 67:996–1000.
   PubMed Web of Science ®Google Scholar
• MCKEAGE MJ, BOXALL FE, JONES M, HARRAP KR: Lack of neurotoxicity of oral bisacetatoammine dichlorocyclohexylamine-platinum(IV)incomparison to cisplatin and tetraplatin in the rat. Cancer Res. 54:629–631.
   Google Scholar
• •Preclinical nerve conduction velocity study in rats showing lack of neurotoxicity of satraplatin relative to tetraplatin and cisplatin.
   Google Scholar
• MELLISH KJ, BARNARD CFJ, MURRER BA, KELLAND LR:DNA-binding properties of novel cis- and trans platinum- based anticancer agents in 2 human ovarian carcinoma cell lines. Int. J. Cancer (1995) 62:717–723.
   PubMed Web of Science ®Google Scholar
• REARDON JT, VAISMAN A, CHANEY SG, SANCAR A: Efficient nucleotide excision repair of cisplatin, oxaliplatin and bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res. (1999) 59:3968–3971.
   PubMed Web of Science ®Google Scholar
• FINK D, NEBEL S, AEBI S et al.: The role of DNA mismatchrepair in platinum drug resistance. Cancer Res. (1996) 56:4881–4886.
   PubMed Web of Science ®Google Scholar
• SHARP SY, ROGERS PM, KELLAND LR: Transport of cisplatin and bis-acetato-ammine-dichloro cyclohexylamine platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance. Clin. Cancer Res. (1995) 1:981–989.
   PubMed Web of Science ®Google Scholar
• MELLISH KJ, KELLAND LR: Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (IV) (JM216) in two human ovarian carcinoma cell lines. Cancer Res. (1994) 54:6194–6200.
   PubMed Web of Science ®Google Scholar
• ORMEROD MG, ORR RM, O'NEILL CF et al.: The cytotoxicaction of four ammine/amine platinum (IV) dicarboxylates: a flow cytometric study. Br. J. Cancer (1996) 74:1935–1943.
   Google Scholar
• O'NEILL CF, KOBERLE B, MASTERS JRW, KELLAND LR: Gene-specific repair of Pt/DNA lesions and induction apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin. Br. J. Cancer (1999) 81:1294–1303.
   PubMed Web of Science ®Google Scholar
• MCKEAGE MJ, MISTRY P, WARD J et al.: A Phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single dose administration. Cancer Chemother. Pharmacol. (1995) 36:451–458.
   PubMed Web of Science ®Google Scholar
• •Initial Phase I study with satraplatin - saturable absorption with bolus dosing.
   Google Scholar
• MCKEAGE MJ, RAYNAUD F, WARD J et al.: Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J. Clin. Oncol. (1997) 15:2691–2700.
   PubMed Web of Science ®Google Scholar
• ••Phase I study of satraplatin using the optimal daily schedulefor five days. Identification of Phase II dose and myelosup-pression as dose-limiting toxicity.
   Google Scholar
• POON GK, RAYNAUD Fl, MISTRY P et al.: Metabolic studies of an orally active platinum anticancer drug by liquid chromatography-electrospray ionization mass spectrometry. Chromatography A (1995) 712:61–66.
   PubMed Web of Science ®Google Scholar
• RAYNAUD Fl, BOXALL FE, GODDARD P, BARNARD CF, MURRER BA, KELLAND LR: Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products. AntiCancer Res. (1996) 16:1857–1862.
   PubMed Web of Science ®Google Scholar
• RAYNAUD Fl, MISTRY P, DONOGHUE A et al.: Biotrans-formation of the platinum drug JM216 following oral administration to cancer patients. Cancer Chemother. Pharmacol. (1996) 38:155–162.
   PubMed Web of Science ®Google Scholar
• •Comprehensive description of biotransformation of satraplatin. Identification of JM118 as main metabolite in patients.
   Google Scholar
• RAYNAUD Fl, ODELL DE, KELLAND LR: Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels. Br. J. Cancer (1996) 74:380–386.
   PubMed Web of Science ®Google Scholar
• ANDO Y, SHIMIZU T, NAKAMURA K et al.: Potent andnon-specific inhibition of cytochrome P450 by JM216, a new oral platinum agent. Br. J. Cancer (1998) 78:1170–1174.
   PubMed Web of Science ®Google Scholar
• BEALE P, RAYNAUD F, HANWELL et al.: Phase I study oforal JM216 given twice daily. Cancer Chemother. Pharmacol. (1998) 42:142–148.
   PubMed Web of Science ®Google Scholar
• SESSA C, MINOIA C, RONCHI A et al.: Phase I clinical andpharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days. Ann. Oncol. (1998) 9:1315–1322.
   PubMed Web of Science ®Google Scholar
• HOFFMAN P, MAUER A, HARAF D et al.: Oral JM216 plusconcomitant radiotherapy (RT) for patients (pts) with advanced malignancies of the chest. Proc. ASCO (1998) 17:488a.
   Google Scholar
• CMELAK AJ, CHOY H, MURPHY BA et al.: Phase I study ofJM216 with concurrent radiation in non-small cell lung cancer and squamous cell head and neck cancer. Proc. ASCO (1999) 18:393a.
   Google Scholar
• JONES SF, GRECO FA, HAINSWORTH JD et al.: Phase Istudy of JM216 in combination with paclitaxel in patients with advanced malignancies. Proc. ASCO (1999) 18:216.
   Google Scholar
• DEMARIO MD, RATAIN MJ, VOGELZANG NJ et al.: A PhaseI study of oral uracil/ftorafur (UFO plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylarnine-platinum IV (W216) each given over 14 days every 28 days. Cancer Chemother. Pharmacol. (1999) 43:385–388.
   PubMed Web of Science ®Google Scholar
• FOKKEMA E, GROEN HJM, BAUER J, UGES DRA, WEIL C, SMITH IE: Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer. J. Clin. Oncol. (1999) 17:3822–3827.
   PubMed Web of Science ®Google Scholar
• ••Most important Phase II trial of satraplatin to date (in smallcell lung cancer).
   Google Scholar
• FOKKEMA E, DR VRIES EGE, MEIJER S, GROEN HJM: Lackof nephrotoxicity of new oral platinum drug JM216 in lung cancer patients. Cancer Chemother. Pharmacol. (2000) 45:89–92.
   PubMed Web of Science ®Google Scholar
• JUDSON I, CERNY T, EPELBAUM R et al.: Phase II trial ofthe oral platinum complex JM216 in non-small-cell lung cancer: An EORTC early clinical studies group investigation. Ann. Oncol. (1997) 8:604–606.
   PubMed Web of Science ®Google Scholar
• •Full report of Phase II trial of satraplatin in non-small cell lung cancer.
   Google Scholar
• PEEREBOOM D, WOOD L, CONNELL C eta/.: Phase II trialof oral platinum (JM216) in hormone refractory prostate cancer (HRPC). Proc. ASCO (1998) 17:314A.
   Google Scholar
• BECOUARN Y, YCHOU M, DUCREUX et al.: Phase II trialof oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. J. Clin. Oncol. (1998) 16:2739–2744.
   PubMed Web of Science ®Google Scholar
• RAYNAUD F, BOXALL F, GODDARD P et al.: Cis-amminedichloro(2-methylpyridine) platinum(1) (AMD473), a novel sterically hindered platinum complex: In vivo activity, toxicology and pharmacokinetics in mice. Clin. Cancer Res. (1997) 3:2063–2074.
   PubMed Web of Science ®Google Scholar
• PRATESI G, PEREGO P, POLIZZI D et al.: A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts. Br. J. Cancer (1999) 80:1912–1919.
   PubMed Web of Science ®Google Scholar
• KIZU R, NAKANISHI T, HAYAKAWA K et al.: A new orally active antitumor 1R,2R-cyclohexanediamine--platinum(IV) complex: trans-(n-valerato) chloro(1R,2R-cyclohexanediamine) (oxalato) platinum(IV). Cancer Chemother. Pharmacol. (1999) 43:97–105.
   PubMed Web of Science ®Google Scholar